跳到正文
原文
Endpoints News 生物医药· Shelby Livingston·· 1 天前AI 评分43

诺和诺德消费者端推进加码,Wegovy口服片与CagriSema蓄势待发

Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck

AI 导读

诺和诺德(Novo Nordisk)消费者端业务推进取得进展,Wegovy口服制剂及在研复方制剂CagriSema相继亮相。Ed Cinca结束四年离开后重返该公司担任CEO,推动产品线布局。上述两个品种均处于申报推进阶段,尚未进入上市应用环节。

正文

LAS VE­GAS — When Ed Cin­ca re­turned to No­vo af­ter four years away, he bare­ly rec­og­nized the place.

“I think the build­ing’s the same, but that’s …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news